ERBB2 and neoplasm: Indeed, Bertotti et al. demonstrated that dual targeting of HER2 and EGFR, such as a combination of lapatinib and pertuzumab or lapatinib and cetuximab, induced tumor regression in a cetuximab-resistant, HER2-amplified CRC PDX mouse model [18].